Objective To analyze the effects of Xiaogan capsule, Xiaoyao pill combined with Shu er capsule on hyperplasia of mammary gland and its effect on vascular endothelial growth factor ( VEGF ) and basic fibroblast growth factor ( bFGF ) .Methods 106 cases of patients with breast hyperplasia treated in our hospital from April 2013 to August 2016 were randomly divided into experimental group and control group according to the order of admission, with 53 cases in each group.The control group was treated with Xiaojin Capsule and Xiaoyao Pills.The experimental group was treated with Xiaojin Capsule, Xiaoyao Pill and Shuerjing Capsule.Analyze the total effective rate of clinical treatment, incidence of adverse reactions, visual analogue pain score and the influence on the expression of VEGF and bFGF in the two groups.Results The total effective rate was 96.23%(51/53) in the experimental group and 86.79%(46/53) in the control group,the total effective rate in the experimental group was much higher than that in the control group (P<0.05).The incidence of adverse reactions was 11.32%(6/53) in the experimental group and 13.21%(7/53) in the control group,there was no significant difference in adverse reactions between the two groups.The visual analogue pain score of the experimental group was (2.85 ±0.41) points, the visual analogue pain score of the control group was (5.25 ±1.84),the visual analogue pain score of the experimental group was significantly lower than that of the control group ( P <0.05 ) .After treatment, the expression of VEGF and bFGF in the patients with hyperplasia of mammary gland decreased, and the levels of VEGF and bFGF in the patients with hyperplasia of mammary glands were significantly higher than those in the untreated group (P<0.05),the expression of VEGF and bFGF in the control group was enhanced.Conclusion Xiaojin capsule,Xiaoyao pill and Shu er jing capsule have higher application value in the patients with hyperplasia of mammary gland , and significantly lower the expression of VEGF and bFGF .

Objective:To study the protective effect of adenosylmethionine tablet on mild liver injury in early pregnancy with chronic hepatitis B virus (HBV) infection and observe the ending of pregnancy.Methods:From January 2017 to December 2018, 46 cases of chronic HBV infected pregnant women with mild abnormal liver function in early pregnancy who were treated in Hangzhou Xixi Hospital were selected as treatment group.Another 53 cases of chronic HBV infected pregnant women with the similar situation of liver function without drug treatment were selected as control group during the same period.The levels of total bilirubin(TB), alanine aminotransferase (ALT), glutamine transaminase(GGT), prothrombin time(PT) and HBV DNA quantification(HBVDNA) were compared between the two groups, and the pregnancy outcome in the two groups was observed.Results:After treatment for 2 weeks, the ALT and GGT levels of the treatment group were significantly lower than those of the control group [(80.85±30.55)U/L vs.(112.79±27.01)U/L( t=-4.26, P<0.05); (30.81±24.26)U/L vs.(44.20±24.89)U/L( t=-2.07, P<0.05)]. The recovery time of liver function in the treatment group[(6.43±2.06)weeks] was significantly shorter than that in the control group [(10.21±3.05)weeks] ( t=-5.66, P<0.05). The fluctuation rate of liver function in the treatment group[21.4%(6/28)] was lower than that in the control group[37.0%(10/37)], but there was no statistically significant difference between the two groups(χ 2=0.27, P=0.60). There were no statistically significant differences between the two groups in the gestational age, fetal distress rate and birth weight(all P>0.05). Conclusion:Adenosylmethionine tablets can improve the liver function of pregnant women with chronic HBV infection, which is helpful for the treatment of liver dysfunction in early pregnancy.The use of adenosylmethionine tablets in early pregnancy has no obvious adverse effect on pregnancy outcome.

AIM: To evaluate the effect of TDF withdrawal time on changes of serum HBV-M, HBV DNA and ALT level in the mother-to-child blocking of the maternal population. METHODS: A prospective, randomized and controlled study was conducted. The 120 pregnant women with HBV who took TDF during 24 to 28 weeks of gestation were randomly divided into group A (withdrawal at delivery) and group B (withdrawal at 4 weeks postpartum), levels of HBV-M, HBV DNA, and ALT at different times were detected. The results were statistically analyzed by Wilcoxon Rank-sum test and χ